Ischemic Stroke Market Report: Trends, Forecast and Competitive Analysis to 2030
It will take 2-3 business days to deliver the report upon receipt the order if any customization is not there.
Ischemic Stroke Trends and Forecast
The future of the global ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets. The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Ischemic Stroke by Segment
The study includes a forecast for the global ischemic stroke by diagnosis, drug class, and region.
Ischemic Stroke Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ischemic stroke companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ischemic stroke companies profiled in this report include-
Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.
CT will remain the largest segment because it ensures short turnaround time and ability to see the brain anatomy in detail.
North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.
Features of the Global Ischemic Stroke Market
Market Size Estimates: Ischemic stroke market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Ischemic stroke market size by diagnosis, drug class, and region in terms of value ($B).
Regional Analysis: Ischemic stroke market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different diagnosis, drug class, and regions for the ischemic stroke market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ischemic stroke market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the ischemic stroke market size?
Answer: The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030.
Q.2 What is the growth forecast for ischemic stroke market?
Answer: The global ischemic stroke market is expected to grow with a CAGR of 7.5% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the ischemic stroke market?
Answer: The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.
Q4. What are the major segments for ischemic stroke market?
Answer: The future of the ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets.
Q5. Who are the key Ischemic Stroke Market companies?
Answer: Some of the key ischemic stroke companies are as follows:
Answer: Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.
Q7. In ischemic stroke market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the ischemic stroke market by diagnosis (CT, MRI, carotid ultrasounds, and cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Ischemic Stroke Market, Ischemic Stroke Market Size, Ischemic Stroke Market Growth, Ischemic Stroke Market Analysis, Ischemic Stroke Market Report, Ischemic Stroke Market Share, Ischemic Stroke Market Trends, Ischemic Stroke Market Forecast, Ischemic Stroke Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
Ischemic Stroke Trends and Forecast
The future of the global ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets. The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Ischemic Stroke by Segment
The study includes a forecast for the global ischemic stroke by diagnosis, drug class, and region.
Ischemic Stroke Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:
- CT
- MRI
- Carotid Ultrasounds
- Cerebral Angiography
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ischemic stroke companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ischemic stroke companies profiled in this report include-
- Abbott Laboratories
- Bayer
- Boehringer Ingelheim
- Boston Scientific Corporation
- Cordis Corporation
- Covidien
- GE Healthcare
- Genentech
- Johnson & Johnson
- Koninklijke Philips N.V.
- Medtronic
Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.
CT will remain the largest segment because it ensures short turnaround time and ability to see the brain anatomy in detail.
North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.
Features of the Global Ischemic Stroke Market
Market Size Estimates: Ischemic stroke market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Ischemic stroke market size by diagnosis, drug class, and region in terms of value ($B).
Regional Analysis: Ischemic stroke market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different diagnosis, drug class, and regions for the ischemic stroke market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ischemic stroke market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the ischemic stroke market size?
Answer: The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030.
Q.2 What is the growth forecast for ischemic stroke market?
Answer: The global ischemic stroke market is expected to grow with a CAGR of 7.5% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the ischemic stroke market?
Answer: The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.
Q4. What are the major segments for ischemic stroke market?
Answer: The future of the ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets.
Q5. Who are the key Ischemic Stroke Market companies?
Answer: Some of the key ischemic stroke companies are as follows:
- Abbott Laboratories
- Bayer
- Boehringer Ingelheim
- Boston Scientific Corporation
- Cordis Corporation
- Covidien
- GE Healthcare
- Genentech
- Johnson & Johnson
- Koninklijke Philips N.V.
Answer: Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.
Q7. In ischemic stroke market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the ischemic stroke market by diagnosis (CT, MRI, carotid ultrasounds, and cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Ischemic Stroke Market, Ischemic Stroke Market Size, Ischemic Stroke Market Growth, Ischemic Stroke Market Analysis, Ischemic Stroke Market Report, Ischemic Stroke Market Share, Ischemic Stroke Market Trends, Ischemic Stroke Market Forecast, Ischemic Stroke Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL ISCHEMIC STROKE MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Ischemic Stroke Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Ischemic Stroke Market by Diagnosis
3.3.1: CT
3.3.2: MRI
3.3.3: Carotid Ultrasounds
3.3.4: Cerebral Angiography
3.4: Global Ischemic Stroke Market by Drug Class
3.4.1: Tissue Plasminogen Activator
3.4.2: Anticoagulant
3.4.3: Antiplatelet
3.4.4: Antihypertensive
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Ischemic Stroke Market by Region
4.2: North American Ischemic Stroke Market
4.2.2: North American Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
4.3: European Ischemic Stroke Market
4.3.1: European Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
4.3.2: European Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
4.4: APAC Ischemic Stroke Market
4.4.1: APAC Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
4.4.2: APAC Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
4.5: ROW Ischemic Stroke Market
4.5.1: ROW Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
4.5.2: ROW Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Ischemic Stroke Market by Diagnosis
6.1.2: Growth Opportunities for the Global Ischemic Stroke Market by Drug Class
6.1.3: Growth Opportunities for the Global Ischemic Stroke Market by Region
6.2: Emerging Trends in the Global Ischemic Stroke Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Ischemic Stroke Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ischemic Stroke Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Abott Laboratories
7.2: Bayer
7.3: Boehringer Ingelheim
7.4: Boston Scientific Corporation
7.5: Cordis Corporation
7.6: Covidien
7.7: GE Healthcare
7.8: Genentech
7.9: Johnson & Johnson
7.10: Koninklijke Philips N.V.
2. GLOBAL ISCHEMIC STROKE MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Ischemic Stroke Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Ischemic Stroke Market by Diagnosis
3.3.1: CT
3.3.2: MRI
3.3.3: Carotid Ultrasounds
3.3.4: Cerebral Angiography
3.4: Global Ischemic Stroke Market by Drug Class
3.4.1: Tissue Plasminogen Activator
3.4.2: Anticoagulant
3.4.3: Antiplatelet
3.4.4: Antihypertensive
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Ischemic Stroke Market by Region
4.2: North American Ischemic Stroke Market
4.2.2: North American Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
4.3: European Ischemic Stroke Market
4.3.1: European Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
4.3.2: European Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
4.4: APAC Ischemic Stroke Market
4.4.1: APAC Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
4.4.2: APAC Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
4.5: ROW Ischemic Stroke Market
4.5.1: ROW Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
4.5.2: ROW Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Ischemic Stroke Market by Diagnosis
6.1.2: Growth Opportunities for the Global Ischemic Stroke Market by Drug Class
6.1.3: Growth Opportunities for the Global Ischemic Stroke Market by Region
6.2: Emerging Trends in the Global Ischemic Stroke Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Ischemic Stroke Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ischemic Stroke Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Abott Laboratories
7.2: Bayer
7.3: Boehringer Ingelheim
7.4: Boston Scientific Corporation
7.5: Cordis Corporation
7.6: Covidien
7.7: GE Healthcare
7.8: Genentech
7.9: Johnson & Johnson
7.10: Koninklijke Philips N.V.
